Effect of Neprilysin Inhibition on Plasma Proteins in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
JACC Heart Fail
.
2025 Jun 17;13(8):102502.
doi: 10.1016/j.jchf.2025.04.012.
Online ahead of print.
Authors
Luqing Zhang
1
,
Brian L Claggett
2
,
Pablo M Marti-Castellote
2
,
Denise Yates
1
,
Michael M Mendelson
1
,
John J V McMurray
3
,
Michael R Zile
4
,
William Chutkow
1
,
Scott D Solomon
5
,
Jonathan W Cunningham
2
Affiliations
1
Novartis Institute for Biomedical Research, Cambridge, Massachusetts, USA.
2
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
3
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom.
4
Ralph H. Johnson Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, South Carolina, USA.
5
Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: ssolomon@bwh.harvard.edu.
PMID:
40532445
PMCID:
PMC12220819
(available on
2026-06-17
)
DOI:
10.1016/j.jchf.2025.04.012
No abstract available
Keywords:
neprilysin; proteomics; sacubitril/valsartan.
Grants and funding
K23 HL168163/HL/NHLBI NIH HHS/United States